EORTC 24051: Unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma (Q61866232)
Jump to navigation
Jump to search
scientific article published in November 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | EORTC 24051: Unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma |
scientific article published in November 2012 |
Statements
EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma (English)
J A Langendijk
Yassine Lalami
Ahmad Awada
Denis Lacombe
Cecilia Liberatoscioli
Catherine Fortpied
Iman El-Hariry
Jan Bogaerts
Jan B Vermorken
16 September 2012